New therapies for castrate-resistant prostate cancer

By Williams Stephen B   Lay Aaron H   Lau Clayton S   Josephson David Y   Wilson Timothy G   Choueiri Toni K   Pal Sumanta K  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 13, 2011-09 ,pp. : 2069-2074

Informa Healthcare

Access to resources Recommend Favorite

Zibotentan for the treatment of castrate-resistant prostate cancer

By Shepard Dale R   Dreicer Robert  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 7, 2010-07 ,pp. : 899-908

Informa Healthcare

Access to resources Recommend Favorite

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

By Schelman William   Liu Glenn   Wilding George   Morris Thomas   Phung De   Dreicer Robert  

Investigational New Drugs, Vol. 29, Iss. 1, 2011-02 ,pp. : 118-125

Springer Publishing Company

Access to resources Recommend Favorite

Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer

By Wissing Michel D   van Diest Paul J   van der Wall Elsken   Gelderblom Hans  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 5, 2013-06 ,pp. : 635-661

Informa Healthcare

Access to resources Recommend Favorite

Prescribing of docetaxel for castrate-resistant prostate cancer has increased following publication of the TAX327 study and NICE recommendations

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 602, 2010-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite